Organogenesis Q1 2025 sees revenue drop, stock plummets

 Organogenesis Holdings (NASDAQ:ORGO) reported its financial results for Q1 2025, revealing a significant decline in revenue and an unexpected operating loss. The company’s stock took a sharp downturn in aftermarket trading, dropping by 18.54% to $4.35. Despite maintaining its full-year revenue guidance, the market reacted negatively to the earnings miss and challenging market conditions. The recent decline comes amid an otherwise strong year for the stock, which has delivered a 67% year-to-date return

• Q1 2025 net revenue decreased by 21% year-over-year to $86.7 million.
• The company reported an operating loss of $26.7 million, up from a $3.9 million loss in Q1 2024.
• Stock price fell by 18.54% in aftermarket trading, reflecting investor concerns.
• Organogenesis reaffirmed its full-year 2025 revenue guidance of $480-$535 million.
• Market uncertainty persists due to delayed LCD implementation.

https://www.investing.com/news/transcripts/earnings-call-transcript-organogenesis-q1-2025-sees-revenue-drop-stock-plummets-93CH-4035028